pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

COMPANY OVERVIEW

Founded in 2015, EdiGene Inc. is headquartered in Beijing and has offices in Guangzhou and Cambridge, USA. EdiGene, Inc. is committed to transforming cutting-edge genome editing technology into a cure for genetic diseases and cancer using their innovative high-throughput genome screening technology.

LOCATION

  • Beijing, , China

  • Guangzhou, , China

  • Cambridge, MA, USA

    • THERAPEUTIC AREAS

  • Oncology

  • Rare Diseases

    • WEBSITE

    https://edigene.com

    CAREER WEBSITE

    https://edigene.com/c.html

    SOCIAL MEDIA

    INVESTORS

    green-pine-capital-partners idg-capital lilly-asia-ventures

    PRESS RELEASES


    May 2, 2023

    EdiGene to Unveil Promising Preclinical POC Data for LEAPER™ 2.0-based in vivo RNA Editing Therapies in NHP Model at the 26th Annual Meeting of ASGCT via Oral Presentation


    Nov 18, 2022

    EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia


    Nov 18, 2022

    EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia


    Nov 7, 2022

    EdiGene Biotechnology Moves into New RandD Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies


    Nov 7, 2022

    EdiGene Biotechnology Moves into New RandD Center at Waltham, Mass. to Advance Proprietary LEAPER™ Technology into Transformative in vivo RNA Editing Therapies


    For More Press Releases
    Google Analytics Alternative